A Complex Case of Psychiatric Issues Associated with HIV Disorder

  • Alana RawanaEmail author
  • Kuppuswami Shivakumar


Despite the substantial efforts that have been made in the identification, pathophysiology and treatment, HIV/AIDS remains a major public health problem. Psychiatric problems such as substance use or dependence can be seen in patients with HIV infection even before the infection has commenced. Several other psychiatric symptoms such as major depression, bipolar disorders, anxiety, delirium, substance use disorders, PTSD and minor neurocognitive motor disorders are commonly comorbid with HIV-related problems. This chapter examines the complex relationships between HIV and psychiatric manifestations with a focus on epidemiology, pathogenesis, clinical presentation and treatment of major psychiatric disorders in HIV infected people.


HIV Psychiatric disorders Depression Anxiety Treatment Assessment 


Disclosure Statement

The authors do not have any disclosures.


  1. 1.
    Altice F, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87. Retrieved from: CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–99. Retrieved from: http:/​/​dx.​doi.​org/​10.​1212/​01.​WNL.​0000287431.​88658.​8b CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Atkinson JH, Heaton RK, Patterson TL, Wolfson T, Deutsch R, Brown SJ, Summers J, Sciolla A, Gutierrez R, Ellis RJ, Abramson I. Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord. 2008;108(3):225–34. Retrieved from: CrossRefPubMedGoogle Scholar
  4. 4.
    American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; text rev.
  5. 5.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.CrossRefGoogle Scholar
  6. 6.
    Bass J, Neugebauer R, Clougherty KF, Verdeli H, Wickramaratne P, Ndogoni L, Speelman L, Weissman M, Bolton P. Group interpersonal psychotherapy for depression in rural Uganda: 6-month outcomes. Br J Psychiatry. 2006;188(6):567–73.CrossRefPubMedGoogle Scholar
  7. 7.
    Beck AT, Steer RA, Brown GK. Beck depression inventory-II. San Antonio: Psychological Corporation; 1996. p. 490–8.Google Scholar
  8. 8.
    Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus–infected adults in the United States. Arch Gen Psychiatry. 2001;58(8):721–8. Scholar
  10. 10.
    Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, Ellis RJ. Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. Clin Neuropsychol. 2012;26(6):894–908. Retrieved from:
  11. 11.
    Blank MB, Himelhoch SS, Balaji AB, Metzger DS, Dixon LB, Rose CE, Oraka E, Davis-Vogel A, Thompson WW, Heffelfinger JD. A multisite study of the prevalence of HIV with rapid testing in mental health settings. Am J Public Health. 2014;104(12):2377–84. Scholar
  12. 12.
    Blank MB, Mandell DS, Aiken L, Hadley TR. Co-occurrence of HIV and serious mental illness among Medicaid recipients. Psychiatr Serv. 2002;53(7):868–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Bolton P, Bass J, Neugebauer R, Verdeli H, Clougherty KF, Wickramaratne P, Speelman L, Ndogoni L, Weissman M. Group interpersonal psychotherapy for depression in rural Uganda: a randomized controlled trial. JAMA. 2003;289(23):3117–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Brouillette MJ, Chouinard G, Lalonde R. Didanosine-induced mania in HIV infection. Am J Psychiatry. 1994;151:1839–40.PubMedGoogle Scholar
  15. 15.
    Brown GR, Rundell JR, McManis SE, Kendall SN, Zachary R, Temoshok L. Prevalence of psychiatric disorders in early stages of HIV infection. Psychosom Med. 1992;54(5):588–601.CrossRefPubMedGoogle Scholar
  16. 16.
    Bühler B, Hambrecht M, Löffler W, an der Heiden W, Häfner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse—a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res. 2002;54(3):243–51. Retrieved from: CrossRefPubMedGoogle Scholar
  17. 17.
    Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatr. 2001;158(5):725–30. Retrieved from: CrossRefPubMedGoogle Scholar
  18. 18.
    Chandra PS, Desai G, Ranjan S. HIV & psychiatric disorders. Indian J Med Res. 2005;121(4):451.PubMedGoogle Scholar
  19. 19.
    Chandra PS, Krishna VA, Ravi V, Desai A, Puttaram S. HIV related admissions in a psychiatric hospital a five year profile. Indian J Psychiatry. 1999;41(4):320.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Chen G, Shen W, Lu M. Implication of serum concentration monitoring in patients with lithium intoxication. Psychiatry Clin Neurosci. 2004;58(1):25–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Clifford DB, Ances BM. HIV-associated neurocognitive disorder. Lancet Infect Dis. 2013;13(11):976–86. Retrieved from: CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Clucas C, Sibley E, Harding R, Liu L, Catalan J, Sherr L A systematic review of interventions for anxiety in people with HIV. Psychol Health Med. 2011;16(5):528–47. Retrieved from:
  23. 23.
    Cozza et al, Psychopharmacological treatment issues in HIV/AIDS Psychiatry , Chapter 42, Comprehensive Textbook of AIDS Psychiatry: A Paradigm for Integrated Care. (By Cohen et al). Oxford University Press, New York, NY .2017.Google Scholar
  24. 24.
    Cozza K, Swanton E, Humphreys C. Hepatotoxicity in combination with valproic acid, ritonavir, and nevirapine: a case report. Psychosomatics. 2000;41(5):452–3.CrossRefPubMedGoogle Scholar
  25. 25.
    Cruess DG, Evans DL, Repetto MJ, Gettes D, Douglas SD, Petitto JM. Prevalence, diagnosis, and pharmacological treatment of mood disorders in HIV disease. Biol Psychiatry. 2003;54(3):307–16.CrossRefPubMedGoogle Scholar
  26. 26.
    Farber EW, McDaniel JS. Clinical management of psychiatric disorders in patients with HIV disease. Psychiatry Q. 2002;73(1):5–16. Retrieved from: CrossRefGoogle Scholar
  27. 27.
    Fernandez F, Ruiz P, editors. Psychiatric aspects of HIV/AIDS. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 355–64.Google Scholar
  28. 28.
    First MB, Williams JBW, Karg RS, Spitzer RL. Structured clinical interview for DSM-5 disorders, clinician version (SCID-5-CV). Arlington: American Psychiatric Association; 2015.Google Scholar
  29. 29.
    Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Fulk LJ, Kane BE, Phillips KD, Bopp CM, Hand GA. Depression in HIV-infected patients: allopathic, complementary, and alternative treatments. J Psychosom Res. 2004;57(4):339–51. Retrieved from: PubMedGoogle Scholar
  31. 31.
    Genis P, Jett M, Bernton EW, Boyle T, Gelbard HA, Dzenko K, Keane RW, Resnick L, Mizrachi Y, Volsky DJ. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med. 1992;176(6):1703–18.CrossRefGoogle Scholar
  32. 32.
    Goldberg DP, Hillier VF. A scaled version of the general health questionnaire. Psychol Med. 1979;9(01):139–45. Cambridge Univ PressCrossRefPubMedGoogle Scholar
  33. 33.
    Grassi B, Gambini O, Scarone S. Notes on the use of fluvoxamine as a treatment of depression in HIV-1-infected subjects. Phamacopsychiatric. 1995;28(3):93–4.CrossRefGoogle Scholar
  34. 34.
    Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Durol AL, Harrel-Joseph LM, Shader RI. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther. 2000;293(2):435–43.PubMedGoogle Scholar
  35. 35.
    Halstead S, Riccio M, Harlow P, Oretti R, Thompson C. Psychosis associated with HIV infection. Br J Psychiatry. 1988;153(5):618–23. Scholar
  36. 36.
    Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Hamilton MA. Development of a rating scale for primary depressive illness. Br J Clin Psychol. 1967;6(4):278–96.CrossRefGoogle Scholar
  38. 38.
    Harris MJ, Jeste DV, Gleghorn A, Sewell DD. New-onset psychosis in HIV-infected patients. J Clin Psychiatry. 1991;52(9):369–76.PubMedGoogle Scholar
  39. 39.
    Hill L, Lee KC. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics. Ann Pharmacother. 2013;47(1):75–89.CrossRefPubMedGoogle Scholar
  40. 40.
    Holland JC, Tross S. The psychosocial and neuropsychiatric sequelae of the acquired immunodeficiency syndrome and related disorders. Ann Intern Med. 1985;103(5):760–4. Scholar
  41. 41.
    Hriso E, Kuhn T, Masdeu JC, Grundman M. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy. Am J Psychiatr. 1991;148:1558–61.CrossRefPubMedGoogle Scholar
  42. 42.
    Johannessen DJ, Wilson LG. Mania with cryptococcal meningitis in two AIDS patients. J Clin Psychiatry. 1988;49(5):200–1.PubMedGoogle Scholar
  43. 43.
    Kalichman SC, Sikkema KJ, Somlai A. Assessing persons with human immunodeficiency virus (HIV) infection using the Beck depression inventory: disease processes and other potential confounds. J Pers Assess. 1995;64(1):86–100.CrossRefPubMedGoogle Scholar
  44. 44.
    Kelly B, Raphael B, Judd F, Perdices M, Kernutt G, Burnett P, Dunne M, Burrows G. Posttraumatic stress disorder in response to HIV infection. Gen Hosp Psychiatry. 1998;20(6):345–52. Retrieved from: CrossRefPubMedGoogle Scholar
  45. 45.
    Kinyanda E, Hoskins S, Nakku J, Nawaz S, Patel V. Prevalence and risk factors of major depressive disorder in HIV/AIDS as seen in semi-urban Entebbe district, Uganda. BMC Psychiatry. 2011;11(1):205. Scholar
  46. 46.
    Kroenke K, Spitzer RL, Williams JB. The phq-9. J Gen Intern Med. 2001;16(9):606–13. Scholar
  47. 47.
    Kroenke K, Spitzer RL, Williams JB. The patient health Questionnaire-2: validity of a two-item depression screener. Med Care. 2003;41:1284–92.CrossRefPubMedGoogle Scholar
  48. 48.
    Letendre SL, Woods SP, Ellis RJ, Atkinson JH, Masliah E, van den Brande G, Durelle J, Grant I, Everall I. HNRC group. Lithium improves HIV-associated neurocognitive impairment. AIDS. 2006;20(14):1885–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Lera G, Zirulnik J. Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Mov Disord. 1999;14(1):128–31.<128::AID-MDS1021>3.0.CO;2-J.CrossRefPubMedGoogle Scholar
  50. 50.
    Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry. 1999;4(4):317–27.CrossRefPubMedGoogle Scholar
  51. 51.
    Lyketsos CG, Schwartz J, Fishman M, Treisman G. AIDS mania. J Neuropsychiatry Clin Nseurosci. 1997;9(2):277–9.CrossRefGoogle Scholar
  52. 52.
    Markowitz JC, Klerman GL, Perry SW. Interpersonal psychotherapy of depressed HIV-positive outpatients. Psychiatr Serv. 1992;43(9):885–90.CrossRefGoogle Scholar
  53. 53.
    Martin L, Kagee A. Lifetime and HIV-related PTSD among persons recently diagnosed with HIV. AIDS Behav. 2011;15(1):125–31.CrossRefPubMedGoogle Scholar
  54. 54.
    Maxwell S, Scheftner WA, Kessler HA, Busch K. Manic syndrome associated with zidovudine treatment. JAMA. 1988;259(23):3406–7. Scholar
  55. 55.
    McDaniel JS, Blalock AC. Mood and anxiety disorders. New Dir Stud Leadersh. 2000;2000(87):51–6.Google Scholar
  56. 56.
    Meyer-Bahlburg H, Nat R, Sugden R, Horwath E. Sexual activity and risk of HIV infection among patients with schizophrenia. Am J Psychiatry. 1994;1(51):229. Retrieved from: Google Scholar
  57. 57.
    Minagar A, Shapshak P, Fujimura R, Ownby R, Heyes M, Eisdorfer C. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci. 2002;202(1):13–23. Retrieved from: CrossRefPubMedGoogle Scholar
  58. 58.
    Mijch AM, Judd FK, Lyketsos CG, Ellen S, Cockram A. Secondary mania in patients with HIV infection: are antiretrovirals protective? J Neuropsychiatry Clin Neurosci. 1999;11(4):475–80. Retrieved from: CrossRefPubMedGoogle Scholar
  59. 59.
    Morrison MF, Petitto JM, Have TT, Gettes DR, Chiappini MS, Weber AL, Brinker-Spence P, Bauer RM, Douglas SD, Evans DL. Depressive and anxiety disorders in women with HIV infection. Am J Psychiatr. 2002;159(5):789–96.CrossRefPubMedGoogle Scholar
  60. 60.
    Nakimuli-Mpungu E, Musisi S, Katabira E, Nachega J, Bass J. Prevalence and factors associated with depressive disorders in an HIV+ rural patient population in southern Uganda. J Affect Disord. 2011;135(1):160–7. Retrieved from: CrossRefPubMedGoogle Scholar
  61. 61.
    Nakimuli-Mpungu E, Musisi S, Mpungu SK, Katabira E. Primary mania versus HIV-related secondary mania in Uganda. Am J Psychiatr. 2006;163(8):1349–54.CrossRefPubMedGoogle Scholar
  62. 62.
    Nasreddine ZS, Chertkow H, Phillips N, Whitehead V, Collin I, Cummings JL. The Montreal cognitive assessment (moca). Neurology. 2004;62(7):A132.Google Scholar
  63. 63.
    Okulicz J, Grandits GA, French JA, et al. The impact of enzyme-inducing antiepileptic drugs on antiretroviral drug levels: a case-control study. Epilepsy Res. 2013;103(2–3):245–53.CrossRefPubMedGoogle Scholar
  64. 64.
    Olatunji BO, Mimiaga MJ, O’Cleirigh C, Safren SA. A review of treatment studies of depression in HIV. Top HIV Med. 2006;14(3):112.PubMedGoogle Scholar
  65. 65.
    Olley BO, Zeier MD, Seedat S, Stein DJ. Post-traumatic stress disorder among recently diagnosed patients with HIV/AIDS in South Africa. AIDS Care. 2005;17(5):550–7. Retrieved from:
  66. 66.
    Owe-Larsson B, Sall L, Salamon E, Allgulander C. HIV infection and psychiatric illness. Afr J Psychiatry. 2009;12(2):115–28.CrossRefGoogle Scholar
  67. 67.
    Pappin M, Wouters E, Booysen FL. Anxiety and depression amongst patients enrolled in a public sector antiretroviral treatment programme in South Africa: a cross-sectional study. BMC Public Health. 2012;12(1):244. Scholar
  68. 68.
    Parenti DM, Simon GL, Scheib RG, Meyer WA, Sztein MB, Paxton H, DiGioia RA, Schulof RS. Effect of lithium carbonate in HIV-infected patients with immune dysfunction. JAIDS J Acquir Immune Defic Syndr. 1988;1(2):119–24.Google Scholar
  69. 69.
    Perkins DO, Stern RA, Golden RN, Murphy C, Naftolowitz D, Evans DL. Mood disorders in HIV infection: prevalence and risk factors in a nonepicenter of the AIDS epidemic. Am J Psychiatry. 1994;151(2):233.CrossRefPubMedGoogle Scholar
  70. 70.
    Pieper AA, Treisman GJ. Depression, mania, and schizophrenia in HIV-infected patients. In: UpToDate. 2017. 7 May 2017.
  71. 71.
    Rabkin JG, Ferrando SJ, Jacobsberg LB, Fishman B. Prevalence of axis I disorders in an AIDS cohort: a cross-sectional, controlled study. Compr Psychiatry. 1997;38(3):146–54. Available at: CrossRefPubMedGoogle Scholar
  72. 72.
    Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.CrossRefGoogle Scholar
  73. 73.
    Romanelli F, Jennings HR, Nath A, Ryan M, Berger J. Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals. Neurology. 2000;54(7):1404–7. http:/​/​dx.​doi.​org/​10.​1212/​WNL.​54.​7.​1404 CrossRefPubMedGoogle Scholar
  74. 74.
    Sacktor NC, Wong M, Nakasujja N, Skolasky RL, Selnes OA, Musisi S, Robertson K, McArthur JC, Ronald A, Katabira E. The international HIV dementia scale: a new rapid screening test for HIV dementia. AIDS. 2005;19(13):1367–74.PubMedGoogle Scholar
  75. 75.
    Safren SA, O’cleirigh C, Tan JY, Raminani SR, Reilly LC, Otto MW, Mayer KH. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28(1):1.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Satz P, Myers HF, Maj M, Fawzy F, Forney DL, Bing EG, Richardson MA, Janssen R. Depression, substance use, and sexual orientation as cofactors in HIV-1 infected men: cross-cultural comparisons. Treat Drug Dependent Individuals Comorbid Mental Disord. 1997;1:130.Google Scholar
  77. 77.
    Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, Gendelman HE, Boska M, Gelbard H. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology. 2006;66(6):919–21. Retrieved from: http:/​/​dx.​doi.​org/​10.​1212/​01.​wnl.​0000204294.​28189.​03 CrossRefPubMedGoogle Scholar
  78. 78.
    Siegel K, Schrimshaw EW. Perceiving benefits in adversity: stress-related growth in women living with HIV/AIDS. Soc Sci Med. 2000;51(10):1543–1554. Retrieved from:
  79. 79.
    Singh AN, Golledge H, Catalan J. Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. J Psychosom Res. 1997;42(5):489–93. Retrieved from: CrossRefPubMedGoogle Scholar
  80. 80.
    Sewell DD. Schizophrenia and HIV. Schizophr Bull. 1996;22(3):465–73. Retrieved from:
  81. 81.
    Shoptaw S, Reback CJ, Peck JA, Yang X, Rotheram-Fuller E, Larkins S, Veniegas RC, Freese TE, Hucks-Ortiz C. Behavioral treatment approaches for methamphetamine dependence and HIV-related sexual risk behaviors among urban gay and bisexual men. Drug Alcohol Depend. 2005;78(2):125–34. Retrieved from: CrossRefPubMedGoogle Scholar
  82. 82.
    Simoni JM, Safren SA, Manhart LE, Lyda K, Grossman CI, Rao D, Mimiaga MJ, Wong FY, Catz SL, Blank MB, DiClemente R. Challenges in addressing depression in HIV research: assessment, cultural context, and methods. AIDS Behav. 2011;15(2):376–88.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Swartz HA, Markowitz JC. Interpersonal psychotherapy for the treatment of depression in HIV-positive men and women. In J. C. Markowitz (Ed.), Review of psychiatry series. Interpersonal psychotherapy (pp. 129-155). Arlington, VA, US: American Psychiatric Association.Google Scholar
  84. 84.
    Thompson A, Silverman B, Dzeng L, Treisman G. Psychotropic medications and HIV. Clin Infect Dis. 2006;42(9):1305–10. Retrieved from: CrossRefPubMedGoogle Scholar
  85. 85.
    Torrey EF. Surviving schizophrenia: a family manual. rev. ed. New York: Perennial Library; 1988.Google Scholar
  86. 86.
    Uddin M, Aiello AE, Wildman DE, Koenen KC, Pawelec G, de Los SR, Goldmann E, Galea S. Epigenetic and immune function profiles associated with posttraumatic stress disorder. Proc Natl Acad Sci. 2010;107(20):9470–5.CrossRefPubMedGoogle Scholar
  87. 87.
    Vitiello B, Burnam MA, Bing EG, Beckman R, Shapiro MF. Use of psychotropic medications among HIV-infected patients in the United States. Am J Psychiatr. 2003;160(3):547–54. Retrieved from: CrossRefPubMedGoogle Scholar
  88. 88.
    Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol Rev. 1997;104(4):667.CrossRefPubMedGoogle Scholar
  89. 89.
    Whetten K, Reif S, Whetten R, Murphy-McMillan LK. Trauma, mental health, distrust, and stigma among HIV-positive persons: implications for effective care. Psychosom Med. 2008;70(5):531–8. Scholar
  90. 90.
    Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev. 2009;19(2):152–68. Retrieved from: CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    World Health Organisation. Composite International Diagnostic Interview (CIDI): a) CIDI-interview (version l.O), b) CIDI-user manual, c) CIDI-training manual d) CIDI-computer programs. Geneva: World Health Organisation; 1990.Google Scholar
  92. 92.
    World Health Organization. International statistical classification of diseases and related health problems. Geneva: World Health Organization; 2004.Google Scholar
  93. 93.
    Wynn GW, Armstrong S. Neurology: antiepileptic drugs. In: Wynn GW, Oesterheld J, Cozza KL, Armstrong S, editors. Clinical manual of drug interaction principles for medical practice. Arlington: American Psychiatric Publishing; 2009. p. 325–52.Google Scholar
  94. 94.
    Zhang W, O’Brien N, Forrest JI, Salters KA, Patterson TL, Montaner JSG, et al. Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada. PLoS One. 2012;7(7):e40793. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Northern Ontario School of MedicineThunder BayCanada
  2. 2.Department of PsychiatryNorthern Ontario School of Medicine (NOSM)SudburyCanada

Personalised recommendations